Ceskova 1993.
Methods | Allocation: randomised (no further description). Blindness: double (administered as monotherapy in oral solution). Duration: 8 weeks. Consent: not stated. Setting: hospital. | |
Participants | Diagnosis: schizophrenia & schizoaffective disorder (ICD‐9). N=62. Sex: 45M, 17F. Age: mean ˜ 36 years. History: hospitalised, chronic with mean duration of illness ˜ 10 years. Exclusions: not stated. | |
Interventions | 1. Risperidone: 2‐20mg/day. N=31.
2. Haloperidol: 2‐20mg/day. N=31. Antiparkinsonian medication, minor tranquillizers or promethazine, dihydroergotamine as required. |
|
Outcomes | Adverse effects: various observed effects.
Leaving the study early.
Discharge from hospital. Unable to use ‐ Global effect: Serejskij's modified scale (no SD). Mental state: BPRS (no SD). Side effects: DVP (no SD), use of antiparkison medication (individual group data not given). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |